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1007-171 Effect of Fosinopril and Pravastatin on Albuminuria in a 
Nonhypertensive, Nonhypercholesterolemic Population
Folkert W. Asselbergs, Hans L. Hillege, Christiane A. Geluk, Ad J. van Boven, Gilles F.H. 
Diercks, Adriaan A. Voors, Paul E. de Jong, Wiek H. van Gilst, University of Groningen, 
Groningen, The Netherlands, University Hospital Groningen, Groningen, The 
Netherlands
Background ACE-inhibition and lipid lowering have shown to reduce the level of albu-
minuria in selected patient populations with hypertension or hypercholesterolemia. PRE-
VEND-IT investigated the effect of fosinopril and pravastatin on albuminuria in non-
hypertensive, non-hypercholesterolemic subjects.
Methods Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a
double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864).
Subjects were randomized to pravastatin 40 mg or matching placebo and to fosinopril
20mg or matching placebo. Key entry criteria were persistent microalbuminuria (15-
300mg/24h), no hypertension (<160/100mmHg) and no hypercholesterolemia (<308 mg/
dl). Microalbuminuria was measured in 2x24 hour urine collection.
Results Mean age was 52.1 ± 11.2 years, 67.5% was male, mean cholesterol was 223
mg/dl, mean systolic and diastolic blood pressure was 131/77 mmHg. The figure below
shows the percentage change of albuminuria after three months and four years of follow-
up. Group A (placebo) and group B (pravastatin 40mg) did not show any effect on the
level of albuminuria. In contrast, group C (fosinopril 20mg) and group D (fosinopril and
pravastatin) significantly reduced the level of albuminuria (p<0.001).
Conclusion In contrast to pravastatin, fosinopril reduces the level of albuminuria signifi-
cantly in subjects without hypertension or hypercholesterolemia.
1007-172 Effect of Fosinopril on Cardiovascular Events in 
Relation to the Intima-Media-Thickness in 
Microalbuminuric Patients Without Hypertension
Folkert W. Asselbergs, Christiane A. Geluk, Arie M. van Roon, Paul E. de Jong, Reinold 
O.B. Gans, Dirk J. van Veldhuisen, Wiek H. van Gilst, University of Groningen, 
Groningen, The Netherlands, University Hospital Groningen, Groningen, The 
Netherlands
Objective To investigate whether the effect of fosinopril on cardiovascular events differs
between subjects with a high or low intima-media-thickness (IMT) in a microalbuminuric
population without hypertension.
Methods Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a
double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864).
Subjects were randomized to fosinopril 20mg or matching placebo. Key entry criteria
were persistent microalbuminuria (15-300mg/24h) and no hypertension (<160/
100mmHg). The IMT was measured at the posterior wall of the left common carotid
artery using radio frequency signal analysis obtained by M-mode ultra-sonography. IMT
was dichotomized (low: IMT <1.0mm, high: IMT >1.0mm).
Results Mean age 51.3 ± 11.8 years, 65% male, mean cholesterol 223 mg/dl, mean sys-
tolic and diastolic blood pressure 130/76 mmHg. During a mean follow-up of 46.2 ± 7.0
months, 42 (4.9%) cardiovascular events occurred. The figure below shows the Cox
regression analysis divided by IMT and treatment. In the subjects with low IMT (group A),
fosinopril reduced the events from 5.3 % to 2.4 %, which is a relative risk reduction of
55%. In the subjects with high IMT (group B), fosinopril reduced the events from 16.3% to
7.8%, a relative risk reduction of 53% (p<0.05).
Conclusion The relative risk reduction in cardiovascular events of fosinopril is equal in
subjects with high and low IMT. However, the absolute risk reduction is much higher in
subjects with a high IMT.
1007-173 Tissue Factor Pathway Inhibition, a New Antithrombotic 
Strategy: Phase-II Study of a Novel, Oral Factor Xa 
Inhibitor
Mohammad Urooj Zafar, Juan Viles-Gonzalez, Carolina Valdiviezo, Sunil X. Anand, 
David A. Vorchheimer, Rogelio Mosqueda, Valentin Fuster, Juan J. Badimon, Mount 
Sinai School of Medicine, New York, NY
Background: Tissue factor (TF) interaction with factors VIIa and Xa (FXa) leads to
thrombin generation. Recent evidence suggests the existence of a systemic pool of TF.
Therefore, TF pathway has become a new therapeutic target in treating atherothrombotic
disease. Current treatment with indirect FXa inhibitors (warfarin and heparin) is effective
in reducing thrombotic events, but is hampered by bleeding and the need for monitoring.
Parenteral direct FXa inhibitors have shown better safety and comparable efficacy to cur-
rent therapy. The availability of an oral FXa inhibitor could extend these benefits to the
ambulatory setting. We report the antithrombotic effects of an oral direct FXa inhibitor
Razaxaban in a clinical study.
Methods: Healthy male subjects (n=20, 27 years ±4.8) were randomized to a single oral
dose of Razaxaban 25 or 100mg. Antithrombotic effects were assessed by changes in
thrombus formation from baseline, using the Badimon perfusion chamber at low and high
shear rates (mimicking venous and arterial flow respectively). Perfusion studies were
done predose, and at 3 and 12 hours postdose. This design allowed each subject to
serve as his own control.
Results: Results for thrombus growth and coagulation parameters are presented in table
below.
Conclusion: Razaxaban, an orally active direct FXa inhibitor, significantly reduced
thrombus formation in a dose-dependent fashion. Inhibition of TF pathway by Razaxaban
may potentially reduce thrombotic complications of cardiovascular disease. 
EFFECT OF RAZAXABAN ON THROMBUS FORMATION AND 
COAGULATION PARAMETERS
Predose 3 Hours Postdose 12 Hours Postdose
25mg
(n=9)
Thrombus Growth:
Low-shear rate 3086 (±201) 2565 (±116) 15%* 2877 (±191) 7%*
High-shear rate 15434 (±750) 12458 (±611) 19%* 14132 (±786) 8%*
Coagulation Parameters:
aPTT 31.0 (±1.4) 32.9 (±1.4) 30.8 (±1.1)
INR 1.0 (±0.0) 1.1 (±0.0) 1.0 (±0.0)
100mg
(n=11)
Thrombus Growth:
Low-shear rate 2685 (±80) 1933 (±125) 28%* 2294 (±90) 15%*
High-shear rate 13864 (±882) 7839 (±526) 42%* 10702 (±623) 21%*
Coagulation Parameters:
aPTT 30.3 (±1.2) 38.4 (±0.9) 32.3 (±0.9)
INR 1.0 (±0.0) 1.8 (±0.1) 1.2 (±0.0)
Results expressed as mean (±standard error) - aPTT in seconds and thrombus size in 
µm2. For 3 and 12 hours postdose, thrombus size results are followed in bold italics by 
% reduction in thrombus size from baseline. * Statistically significant (p<0.05).
